Corporate and Pipeline Strategy and Development Roadmap

The Client

• Midsize Pharmaceutical company with T-cell modulating technology platform developing therapies for autoimmune and allergic diseases and conditions
• Pipeline consists of a single early clinical asset advancing for rheumatoid arthritis (with long runway to value inflection) and multiple preclinical assets

Challenge

• Select top AIID indications to validate platform, balance development and commercial risk, and enable optionality to go-to-market alone vs needing a partner
• Prepare development strategy and roadmap, accounting for differential time, value, cost and risk, to strategically sequence asset advancement and build a robust pipeline

Approach

• Secondary research and KOL workshops to inform assessment of technology platform and pipeline strategy
• Identified and ranked and developed target product profiles (TPPs) for platform-leverageable AIID indications
• Developed development roadmap for select AIID indications and Board deck supporting recommendations

Valued Outcome

• Rationale and selection of top platform-leverageable AIID indications
• TPPs of select AIID indications to inform development
• Development strategy and roadmap balancing time, value, cost and risk to build robust AIID pipeline and generate significant near- and long-term value